For its third fiscal quarter (ending September 30), Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) has reported a -37% decline in E.P.S. from $-2.23 a year ago to $-1.40 in the current quarter. For the latest four quarters through September 30, E.P.S. were $-6.43 compared to $-8.97 a year ago — a decline of -28%.
Recent Price Action
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) stock closed at $52.18 on 11/5/24 after a large increase of 2.2%. Moreover, this advance was accompanied by exceptionally high trading volume at 260% of normal. The stock has declined -1.7% during the last week but has been strong relative to the market over the last nine months.
Current PriceTarget Research Rating
RARE is expected to be a modest Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
Ultragenyx Pharmaceutical has a current Value Trend Rating of D (Negative). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Ultragenyx Pharmaceutical has a very low Appreciation Score of 3 but a good Power Rating of 74, producing the Negative Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment